This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2010 Jul;150(1):119-21.

doi: 10.1111/j.1365-2141.2010.08168.x. Epub 2010 Apr 5.

Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study

Antonella Poloni, Debora Capelli, Silvia Trappolini, Benedetta Costantini, Mauro Montanari, Guido Gini, Ilaria Scortechini, Giorgia Mancini, Giancarlo Discepoli, Pietro Leoni, Attilio Olivieri

PMID: 20377587
DOI: 10.1111/j.1365-2141.2010.08168.x

Clinical Trial

Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study

Antonella Poloni et al. Br J Haematol. 2010 Jul.

. 2010 Jul;150(1):119-21.

doi: 10.1111/j.1365-2141.2010.08168.x. Epub 2010 Apr 5.

Authors

Antonella Poloni, Debora Capelli, Silvia Trappolini, Benedetta Costantini, Mauro Montanari, Guido Gini, Ilaria Scortechini, Giorgia Mancini, Giancarlo Discepoli, Pietro Leoni, Attilio Olivieri

PMID: 20377587
DOI: 10.1111/j.1365-2141.2010.08168.x

No abstract available

PubMed Disclaimer

Similar articles

Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.
Ichikawa M, Hangaishi A, Nannya Y, Kurokawa M. Ichikawa M, et al. Int J Hematol. 2010 Nov;92(4):673-4. doi: 10.1007/s12185-010-0711-9. Epub 2010 Oct 28. Int J Hematol. 2010. PMID: 20978876 No abstract available.
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Castaigne S, et al. Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Lancet. 2012. PMID: 22482940 Clinical Trial.
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Ronconi S, Visani G, Baccarani M. Piccaluga PP, et al. Haematologica. 2003 Dec;88(12):ECR37. Haematologica. 2003. PMID: 14688010 No abstract available.
[Molecular target therapy--gemtuzumab ozogamicin].
Usui N. Usui N. Nihon Rinsho. 2007 Jan 28;65 Suppl 1:494-8. Nihon Rinsho. 2007. PMID: 17474454 Review. Japanese. No abstract available.
The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.
Pagano L, Fianchi L, Caira M, Rutella S, Leone G. Pagano L, et al. Oncogene. 2007 May 28;26(25):3679-90. doi: 10.1038/sj.onc.1210364. Oncogene. 2007. PMID: 17530021 Review.

See all similar articles

Cited by

Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.
Ichikawa M, Hangaishi A, Nannya Y, Kurokawa M. Ichikawa M, et al. Int J Hematol. 2010 Nov;92(4):673-4. doi: 10.1007/s12185-010-0711-9. Epub 2010 Oct 28. Int J Hematol. 2010. PMID: 20978876 No abstract available.
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.
Capelli D, Saraceni F, Fiorentini A, Chiarucci M, Menotti D, Poloni A, Discepoli G, Leoni P, Olivieri A. Capelli D, et al. Adv Ther. 2020 May;37(5):2288-2302. doi: 10.1007/s12325-020-01310-4. Epub 2020 Apr 15. Adv Ther. 2020. PMID: 32297279 Free PMC article.
Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Xu Q, He S, Yu L. Xu Q, et al. Front Immunol. 2021 Aug 16;12:683595. doi: 10.3389/fimmu.2021.683595. eCollection 2021. Front Immunol. 2021. PMID: 34484181 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information